Skip to main content
. 2021 Nov 25;13(23):5922. doi: 10.3390/cancers13235922

Table 3.

Representation of answers to questions by intensity of side effects.

P2c D2c p P3c D3c p P4c D4c p
No side-effects reported
None 824 (66.3) 975 (78.5) <0.001 780 (62.8) 910 (73.3) 0.002 796 (64.1) 918 (73.9) 0.003
Reported side-effects
Mild 169 (13.6) 142 (11.4) 0.126 151 (12.2) 187 (15.1) 0.050 165 (13.3) 188 (15.1) 0.221
Moderate 163 (13.1) 85 (6.8) <0.001 195 (15.7) 73 (5.9) <0.001 168 (13.5) 61 (4.9) <0.001
Severe 86 (6.9) 40 (3.2) <0.001 116 (9.3) 72 (5.8) 0.001 113 (9.0) 75 (6.0) 0.006
Total 418 267 <0.001 462 332 <0.001 446 324 <0.001

P2c = patient second cycle; D2c = physician second cycle; P3c = patient third cycle; D3c = physician third cycle; P4c = patient fourth cycle; D4c = physician fourth cycle. p-level of statistical significance of patients and physicians based on chi-square test. with zero degrees of freedom (assuming equal frequency of reporting side effects at. expected frequencies).